CL2015002736A1 - Composición farmacéutica de clorhidrato de s-ketamina. - Google Patents

Composición farmacéutica de clorhidrato de s-ketamina.

Info

Publication number
CL2015002736A1
CL2015002736A1 CL2015002736A CL2015002736A CL2015002736A1 CL 2015002736 A1 CL2015002736 A1 CL 2015002736A1 CL 2015002736 A CL2015002736 A CL 2015002736A CL 2015002736 A CL2015002736 A CL 2015002736A CL 2015002736 A1 CL2015002736 A1 CL 2015002736A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
ketamine hydrochloride
ketamine
depression
preservant
Prior art date
Application number
CL2015002736A
Other languages
English (en)
Inventor
Johanna Bentz
Roger C A Embrechts
Nico Rudolph Niemeijer
Esther D G Basstanie
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50687638&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002736(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2015002736A1 publication Critical patent/CL2015002736A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Emergency Medicine (AREA)

Abstract

COMPOSICION FARMACEUTICA QUE COMPRENDE CLORHIDRATO DE S-KETAMINA Y AGUA TAL QUE NO CONTIENE UN CONSERVANTE ANTIMICROBIANO, PARA LA ADMINSITRACIÓN NASAL; UTIL EN EL TRATAMIENTO DE LA DEPRESION, TAL COMO TRASTORNO DEPRESIVO MAYOR, DEPRESION UNIPOLAR, ANSIOSA Y BIPOLAR, ENTRE OTRAS
CL2015002736A 2013-03-15 2015-09-15 Composición farmacéutica de clorhidrato de s-ketamina. CL2015002736A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361791237P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
CL2015002736A1 true CL2015002736A1 (es) 2016-03-28

Family

ID=50687638

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002736A CL2015002736A1 (es) 2013-03-15 2015-09-15 Composición farmacéutica de clorhidrato de s-ketamina.

Country Status (16)

Country Link
US (5) US20140275278A1 (es)
EP (2) EP3636251B1 (es)
KR (1) KR102217616B1 (es)
CN (2) CN105073096A (es)
AU (2) AU2014240102A1 (es)
BR (1) BR112015022972B1 (es)
CL (1) CL2015002736A1 (es)
CR (1) CR20150481A (es)
ES (2) ES2755809T3 (es)
MX (1) MX371392B (es)
MY (1) MY180526A (es)
NI (1) NI201500135A (es)
PE (1) PE20200404A1 (es)
PH (1) PH12015502013B1 (es)
SG (2) SG10201802104QA (es)
WO (1) WO2014152196A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3043785T3 (da) 2013-09-13 2021-11-15 Univ Chiba Nat Univ Corp Anvendelse af r-ketamin og salt deraf som lægemidler
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
EP3297620A4 (en) 2015-06-27 2019-01-09 Shenox Pharmaceuticals, LLC TRANSDERMAL DELIVERY SYSTEM FOR KETAMINE
CN106562952B (zh) * 2015-10-09 2020-06-09 江阴安博生物医药有限公司 氯胺酮在治疗重性抑郁障碍中的应用
WO2017139382A1 (en) * 2016-02-08 2017-08-17 The Texas A&M University System Combination of adjuvant drugs esketamine and brimonidine for medical treatments
US20180177744A1 (en) * 2016-12-22 2018-06-28 Gary Jay Method of treating pain and depression using a hybrid mixture of s-ketamine and r-ketamine
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
EP3505157B1 (en) 2017-12-29 2021-12-08 Celon Pharma S.A. Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
JPWO2019160057A1 (ja) 2018-02-15 2021-02-04 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
MX2020011653A (es) 2018-05-04 2021-02-09 Perception Neuroscience Inc Métodos de tratamiento para el abuso de sustancias.
US11154537B2 (en) 2018-08-10 2021-10-26 Eleusis Therapeutics Us, Inc. Method of treatment for ketamine infusion
EP3628313A1 (en) 2018-09-28 2020-04-01 Celon Pharma S.A. Ketamine composition for use in a method of treatment of depression by pulmonary administration
AU2020231172A1 (en) 2019-03-05 2021-09-23 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
KR20220012922A (ko) 2019-05-31 2022-02-04 셀론 파르마 에스.에이. 약학적 조성물의 전자적으로 관리된 투여
US20220226586A1 (en) 2019-05-31 2022-07-21 Celon Pharma S.A. An Inhaler For Electronically Supervised Parenteral Administration of a Pharmaceutical Composition
FI3976012T3 (fi) 2019-05-31 2024-04-05 Afyx Therapeutics As Ketamiinin intranasalinen annostus klusteripäänsärkypotilaille
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
CN114306218B (zh) * 2020-09-30 2023-11-10 四川普锐特药业有限公司 满足药学抑菌要求的经粘膜给药r-氯胺酮药物组合物
CN113813250B (zh) * 2021-07-21 2023-05-05 广州新济药业科技有限公司 含氯胺酮的药物组合物及其制备方法和应用
WO2023207729A1 (zh) * 2022-04-26 2023-11-02 宜昌人福药业有限责任公司 艾司氯胺酮液体制剂及其用途

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
JPS632932A (ja) * 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US4994467A (en) 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
DE4312016A1 (de) * 1993-04-13 1994-10-20 Goedecke Ag Stabile Ketamin-Lösungen
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
AU733284B2 (en) 1995-02-24 2001-05-10 Stuart L. Weg Nasal and ocular administration of ketamine to manage pain and for detoxification
WO1997007750A1 (en) 1995-08-30 1997-03-06 Weg Stuart L Administration of ketamine to manage pain and to reduce drug dependency
FR2739294B1 (fr) 1995-09-29 1998-01-16 Lhd Lab Hygiene Dietetique Embout nasal de securite
DE19619665C2 (de) 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
DE19723133A1 (de) 1997-06-03 1998-12-10 Caideil M P Teoranta Tourmakea Austragvorrichtung für Medien
FR2764807B1 (fr) 1997-06-18 1999-08-20 Valois Sa Dispositif de distribution nasale d'un produit fluide ou pulverulent
BR9912395A (pt) * 1998-07-24 2001-10-16 Seo Hong Yoo Preparação de formas de dosagem de solução clara aquosa com ácidos biliares
US6599883B1 (en) 1998-10-30 2003-07-29 Nastech Pharmaceutical Company, Inc. Nasal delivery of xylitol
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
US6017961A (en) 1999-07-08 2000-01-25 Flores; John Anthony Ketamine and n-butyl-p-aminobezoate in PLO
EP1103256A1 (de) 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
EP1328214A4 (en) 2000-09-20 2009-07-29 Shahinian Lee Jr NASAL, INHALABLE AND LOCAL OPHTHALMIC PREPARATIONS AND MEDICATIONS WITH SPONTANEOUS CONSERVATION
US6881731B1 (en) 2000-10-23 2005-04-19 Shanbrom Technologies, Llc Enhancers for microbiological disinfection
WO2004010932A2 (en) 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
AU2003291037A1 (en) 2002-11-18 2004-06-15 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US20040214215A1 (en) * 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US8082173B2 (en) 2003-05-22 2011-12-20 Cecil Kost Drug sample fulfillment architecture
US20040265364A1 (en) 2003-06-25 2004-12-30 Binnur Ozturk Neuropathy cream
US20050095277A1 (en) 2003-06-25 2005-05-05 Binnur Ozturk Neuropathy cream
US20060223788A1 (en) 2005-03-29 2006-10-05 Cathcart Clifton H Analgesic composition for topical use
EP1885414B1 (en) 2005-06-01 2012-11-21 SHL Group AB Device for delivering medicament
US20060276550A1 (en) 2005-06-03 2006-12-07 Dileep Bhagwat Topical compositions of ketamine and butamben and methods of their use
CN101466364A (zh) * 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
US20070256688A1 (en) 2006-04-21 2007-11-08 Aradigm Corporation Mechanical single dose intrapulmonary drug delivery devices
RU2008150624A (ru) 2006-05-22 2010-06-27 Ванда Фармасьютиклз, Инк. (Us) Лечение депрессивных расстройств
DE102007009888A1 (de) * 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
WO2008151179A2 (en) 2007-06-04 2008-12-11 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
WO2009131794A1 (en) 2008-03-27 2009-10-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
MX2010012234A (es) * 2008-05-13 2011-03-03 Clarassance Inc Cc10 humana recombinante y composiciones del mismo para uso en el tratamiento de rinitis nasal.
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
EP2992877A1 (en) 2010-06-15 2016-03-09 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
US9073819B2 (en) 2011-06-30 2015-07-07 University Of South Florida Compositions, methods of use, and methods of treatment
JP6296985B2 (ja) 2011-10-14 2018-03-20 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ うつ病及び神経障害性疼痛の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミン、（ｓ）−デヒドロノルケタミン及び他の（ｒ，ｓ）−ケタミンの立体異性デヒドロ及びヒドロキシル化代謝生成物の使用
JP6285865B2 (ja) 2011-11-14 2018-02-28 アルファシグマ ソシエタ ペル アチオニ うつ病を有する対象のための処置レジメンを選択するためのアッセイ及び方法
US20130209585A1 (en) 2012-02-13 2013-08-15 Stanley Kim Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy
CN104519878A (zh) 2012-03-12 2015-04-15 詹森药业有限公司 用于治疗顽固性或难治性抑郁症的艾氯胺酮
AU2016203771A1 (en) 2012-03-13 2016-06-23 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
US20150057306A1 (en) 2012-03-30 2015-02-26 The General Hospital Corporation Compositions comprising scopolamine and ketamine in the treatment of depression
US20140079740A1 (en) 2012-08-02 2014-03-20 ClinPharm Support GmbH Oral transmucosal adminstration forms of s-ketamine
US20140057988A1 (en) 2012-08-23 2014-02-27 Stuart WEG Anxiolytic composition, formulation and method of use
FR2994844B1 (fr) 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine
NZ619257A (en) 2012-10-08 2015-07-31 Auckland Uniservices Ltd Ketamine derivatives
ES2484068B1 (es) 2013-02-08 2015-04-16 Ana MÍNGUEZ MARTÍ Una composición farmacéutica que contiene ketamina y amitriptilina
CN112057441A (zh) 2013-04-12 2020-12-11 西奈山伊坎医学院 创伤后应激障碍的治疗方法
JP2016531913A (ja) 2013-08-26 2016-10-13 アモーサ セラピューティックス， インコーポレイテッドＡｍｏｒｓａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 神経抑制性ケタミンの単層による経口投与
DK3043785T3 (da) 2013-09-13 2021-11-15 Univ Chiba Nat Univ Corp Anvendelse af r-ketamin og salt deraf som lægemidler
US9569220B2 (en) 2013-10-06 2017-02-14 Synopsys, Inc. Processor branch cache with secondary branches
CN103705909A (zh) 2013-12-16 2014-04-09 陈镜伊 一种无痛人流用药
WO2015101693A1 (es) 2013-12-31 2015-07-09 Servicio Andaluz De Salud Composiciones y preparaciones combinadas para el tratamiento de las algias orofaríngeas
WO2015108985A1 (en) 2014-01-14 2015-07-23 Children's Hospital Medical Center Compositions comprising ketamine for treating an autism spectrum disorder
PL3131533T3 (pl) 2014-04-17 2019-12-31 Develco Pharma Schweiz Ag Doustna postać dawkowania ketaminy
JP6429898B2 (ja) 2014-05-04 2018-11-28 フイルメニツヒ ソシエテ アノニムＦｉｒｍｅｎｉｃｈ Ｓａ フレーバー付きの食品製品および飲料製品
FR3023188B1 (fr) 2014-07-04 2016-08-19 Aptar France Sas Dispositif de distribution de produit fluide.
KR20170040800A (ko) 2014-08-13 2017-04-13 얀센 파마슈티카 엔.브이. 우울증 치료 방법
EP3725307A1 (en) 2014-09-15 2020-10-21 Janssen Pharmaceutica NV Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression
WO2016109427A1 (en) 2014-12-31 2016-07-07 Icahn School Of Medicine At Mount Sinai Method of maintaining the anti-depressant effect of ketamine with lithium
CN104798728A (zh) 2015-05-08 2015-07-29 南京中医药大学 产后抑郁动物模型的建立方法及其应用
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
EP3297620A4 (en) 2015-06-27 2019-01-09 Shenox Pharmaceuticals, LLC TRANSDERMAL DELIVERY SYSTEM FOR KETAMINE
US20180296478A1 (en) 2016-02-12 2018-10-18 Synergistic Therapeutics, Llc Sublingual antidepressant and antianxiety tablet
US20180042936A1 (en) 2016-03-18 2018-02-15 Genomind, Inc. Maintenance therapy using tianeptine
BR112020012473A2 (pt) 2017-12-22 2020-11-24 Janssen Pharmaceuticals, Inc. escetamina para o tratamento da depressão

Also Published As

Publication number Publication date
NI201500135A (es) 2016-03-16
MX371392B (es) 2020-01-28
EP3636251B1 (en) 2022-01-19
US20200069612A1 (en) 2020-03-05
AU2019200424A1 (en) 2019-02-14
AU2019200424A8 (en) 2019-02-21
CN105073096A (zh) 2015-11-18
ES2755809T3 (es) 2020-04-23
SG11201507347QA (en) 2015-10-29
US20140274981A1 (en) 2014-09-18
KR20150132381A (ko) 2015-11-25
MX2015012617A (es) 2016-06-21
PE20200404A1 (es) 2020-02-26
CR20150481A (es) 2015-10-26
PH12015502013A1 (en) 2016-01-11
BR112015022972A2 (pt) 2017-07-18
EP2968122A1 (en) 2016-01-20
AU2014240102A1 (en) 2015-09-17
EP3636251A1 (en) 2020-04-15
US11446260B2 (en) 2022-09-20
BR112015022972B1 (pt) 2023-02-14
SG10201802104QA (en) 2018-05-30
WO2014152196A1 (en) 2014-09-25
MY180526A (en) 2020-12-01
ES2911466T3 (es) 2022-05-19
KR102217616B1 (ko) 2021-02-19
AU2019200424B2 (en) 2020-05-14
CN111643449A (zh) 2020-09-11
PH12015502013B1 (en) 2016-01-11
US20230241009A1 (en) 2023-08-03
US20140275278A1 (en) 2014-09-18
EP2968122B1 (en) 2019-08-28
US20190117591A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
CL2015002736A1 (es) Composición farmacéutica de clorhidrato de s-ketamina.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CY1121928T1 (el) Φαρμακευτικη συνθεση υδροχλωρικης s-κεταμινης
CO2017001994A2 (es) Compuestos activos hacia bromodominios
DOP2015000241A (es) Compuestos de biaril-amida como inhibidores de cinasa
NI201600071A (es) Compuestos de inhibidor de autotaxina
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
CL2015001461A1 (es) Una formulación estabilizada de pemetrexed.
CO6821938A2 (es) Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
DOP2016000226A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
ECSP12011735A (es) Composiciones que comprenden tramadol y celecoxib en el tratamiento del dolor
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
CL2015001640A1 (es) Heterociclos n-acetilados y de nitrógeno saturados que potencian la actividad de un antibiótico activo contra micobacterias
CO2017012645A2 (es) Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
BR112018007625A2 (pt) composição antibacteriana combinada e regime antibacteriano de curto prazo
CL2016000884A1 (es) Derivados de piperazina y su uso como medicamento.
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
CL2016001570A1 (es) Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas
BR112017007863A2 (pt) composição para o tratamento de condições envolvendo dor muscular
AR100444A1 (es) Uso de palmitoiletanolamida en combinación de opioides
FR3025096B1 (fr) Composition gel/gel contenant un actif anti-transpirant
BR112015025781A2 (pt) composição farmacêutica para uso inalatório e kit para a administração de um fármaco como um pó inalatório